<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642782</url>
  </required_header>
  <id_info>
    <org_study_id>DIOPSYS</org_study_id>
    <nct_id>NCT03642782</nct_id>
  </id_info>
  <brief_title>Evaluation of the Electroretinogram Pattern (Diopsys® NOVA System) for the Early Diagnosis of Glaucoma</brief_title>
  <acronym>DIOPSYS</acronym>
  <official_title>Evaluation of the Electroretinogram Pattern (Diopsys® NOVA System) for the Early Diagnosis of Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Paris Saint Joseph</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Paris Saint Joseph</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is a common and potentially blinding disease. It is characterized by an optic nerve
      damage, a visual field defect and elevated intraocular pressure (IOP).

      The loss of retinal nerve fibers is accompanied by functional impairment in the territories
      corresponding to deficits of the visual field. However, this structure-function relationship
      is not always found initially. These discrepancies are mainly chronological: the structural
      damage preceding the functional impairment sometimes of several years
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The electroretinogram pattern (ERGP) is an electrophysiological exploration technique that
      reflects the activity of retinal ganglion cells. It presents itself as an objective field of
      vision that does not require the active collaboration of the patient. It consists in
      recording the electrical activity of functional retinal ganglion cells following a light
      stimulation. Simple (30 minutes maximum), it could improve the detection of early forms of
      glaucoma. A significant ERGP is also thought to be correlated with peripapillary and macular
      CNP structural involvement of the ganglionic complex in early forms of glaucoma (MD&gt; -6 dB).

      Some results even suggest that ganglion dysfunction could be detected by the ERGP eight years
      on average before the occurrence of detectable alterations on the RNFL OCT. ERGP is already
      recognized as a routine examination for monitoring glaucomatous patients (review side in
      nomenclature and reimbursed by Social Security) but it could therefore be used as a
      diagnostic tool in very early forms of intraocular hypertonia glaucoma so to objectify signs
      of preperimetric functional impairment in order to establish a suitable hypotonizing
      treatment and to improve the prognosis of this disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 3, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlations between Electroretinogram Pattern, vision field and optical coherence tomography</measure>
    <time_frame>Time of inclusion</time_frame>
    <description>Electroretinogram Patterny : Magnitude, magnitude D, Magnitude D/Magnitude ratio.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlations between Electroretinogram Pattern, vision field and optical coherence</measure>
    <time_frame>Time of inclusion</time_frame>
    <description>Vision field: mean deviation, corrected pattern standard deviation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlations between Electroretinogram Pattern, vision field and optical coherence</measure>
    <time_frame>Time of inclusion</time_frame>
    <description>Optical coherence tomography: retinal nerve fiber layer thickness and macular analysis of the ganglionic complex.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>early age of glaucoma or with important risk factors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients included will benefit from a complete ophtalmic examination including visual acuity, slit lamp biomicroscopic examination of the anterior segment, measurement of intraocular pressure by Goldmann tonometer aplanation, dynamic gonioscopy with Posner glass. They will also have a fundus examination with examination of the retina, macula and optic nerve as well as the ERGP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electroretinogram Pattern (Diopsys® NOVA System)</intervention_name>
    <description>it's an additional examination that extends the duration of the ophthalmological consultation by 30 minutes</description>
    <arm_group_label>early age of glaucoma or with important risk factors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man and woman age ≥ 18 years

          -  Francophone

          -  Patient with medical insurance

          -  Refraction: sphere ± 5.0 D and cylinder ± 3.0 D

          -  Pupillary diameter ≥ 3mm

          -  Early glaucoma patients :

               -  Intraocular pressure&gt; 21 mmHg or &lt;21mmHg under treatment

               -  Thickness of pathological retinal nerve fibers with at least one affected area
                  (OCT)

               -  At least one reliable visual field (false positives, false negatives and fixation
                  losses ≤ 25%) and no artifacts, with Corrected Pattern Standard Deviation (CPSD)
                  pathological in the 5% and Glaucoma Hemifield Pathological test and an early
                  attack (MD&gt; -6dB)

          -  Patient at risk for glaucoma with:

               -  And / or family history of glaucoma

               -  and / or intraocular pressure&gt; 21 mmHg

               -  and / or retinal nerve fibers (pathological thickness in at least one area on the
                  OCT)

               -  and / or reliable visual field (false positives, false negatives and fixation
                  losses ≤ 25%) and without artifact, with pathological Corrected Pattern Standard
                  Deviation (CPSD) in the 5% and Glaucoma Hemifield Pathological Test and an early
                  onset (MD&gt; -6 dB).

        Exclusion Criteria:

          -  Visual acuity below 20/30 (Snellen scale or equivalent on another visual acuity scale)

          -  Unreliable visual field (false positives, loss of fixation and false negatives&gt; 25%)

          -  History of intraocular surgery (except uncomplicated cataract surgery)

          -  Ocular pathology other than associated glaucoma

          -  Neurological disease affecting the visual field or the optic nerve

          -  History of macular laser or pan retinal photocoagulation

          -  Unreliable ERGP pattern

          -  Offset OCT, unreliable

          -  Refusal to participate in the study

          -  Patient under tutorship or curatorship

          -  Patient deprived of liberty

          -  Epileptic patient

          -  Eczema of the eyelids or allergy to one of the components of the electrodes or skin
             gel allowing the cleaning of the skin before the positioning of the electrodes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>LACHKAR Yves, Professor</last_name>
    <phone>+ 33 1 44 12 37 95</phone>
    <email>ylachkar@hpsj.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>GRABER Martin, MD</last_name>
    <email>mgraber@hpsj.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène BEAUSSIER, PhD, PharmD</last_name>
      <phone>+ 33 1 44 12 70 38</phone>
      <email>crc@hpsj.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30.</citation>
    <PMID>12049575</PMID>
  </results_reference>
  <results_reference>
    <citation>Quigley HA, Dunkelberger GR, Green WR. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol. 1989 May 15;107(5):453-64.</citation>
    <PMID>2712129</PMID>
  </results_reference>
  <results_reference>
    <citation>Harwerth RS, Quigley HA. Visual field defects and retinal ganglion cell losses in patients with glaucoma. Arch Ophthalmol. 2006 Jun;124(6):853-9.</citation>
    <PMID>16769839</PMID>
  </results_reference>
  <results_reference>
    <citation>Sommer A, Katz J, Quigley HA, Miller NR, Robin AL, Richter RC, Witt KA. Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. Arch Ophthalmol. 1991 Jan;109(1):77-83.</citation>
    <PMID>1987954</PMID>
  </results_reference>
  <results_reference>
    <citation>Hwang YH, Kim YY, Kim HK, Sohn YH. Ability of cirrus high-definition spectral-domain optical coherence tomography clock-hour, deviation, and thickness maps in detecting photographic retinal nerve fiber layer abnormalities. Ophthalmology. 2013 Jul;120(7):1380-7. doi: 10.1016/j.ophtha.2012.12.048. Epub 2013 Mar 28.</citation>
    <PMID>23541761</PMID>
  </results_reference>
  <results_reference>
    <citation>Tan O, Chopra V, Lu AT, Schuman JS, Ishikawa H, Wollstein G, Varma R, Huang D. Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography. Ophthalmology. 2009 Dec;116(12):2305-14.e1-2. doi: 10.1016/j.ophtha.2009.05.025. Epub 2009 Sep 10.</citation>
    <PMID>19744726</PMID>
  </results_reference>
  <results_reference>
    <citation>Na JH, Lee K, Lee JR, Baek S, Yoo SJ, Kook MS. Detection of macular ganglion cell loss in preperimetric glaucoma patients with localized retinal nerve fibre defects by spectral-domain optical coherence tomography. Clin Exp Ophthalmol. 2013 Dec;41(9):870-80. doi: 10.1111/ceo.12142. Epub 2013 Jul 5.</citation>
    <PMID>23777476</PMID>
  </results_reference>
  <results_reference>
    <citation>Mwanza JC, Oakley JD, Budenz DL, Anderson DR; Cirrus Optical Coherence Tomography Normative Database Study Group. Ability of cirrus HD-OCT optic nerve head parameters to discriminate normal from glaucomatous eyes. Ophthalmology. 2011 Feb;118(2):241-8.e1. doi: 10.1016/j.ophtha.2010.06.036. Epub 2010 Oct 28.</citation>
    <PMID>20920824</PMID>
  </results_reference>
  <results_reference>
    <citation>Hwang YH, Kim YY. Glaucoma diagnostic ability of quadrant and clock-hour neuroretinal rim assessment using cirrus HD optical coherence tomography. Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2226-34. doi: 10.1167/iovs.11-8689.</citation>
    <PMID>22410556</PMID>
  </results_reference>
  <results_reference>
    <citation>De Jong LA, Snepvangers CE, van den Berg TJ, Langerhorst CT. Blue-yellow perimetry in the detection of early glaucomatous damage. Doc Ophthalmol. 1990 Oct;75(3-4):303-14.</citation>
    <PMID>2090405</PMID>
  </results_reference>
  <results_reference>
    <citation>Felius J, de Jong LA, van den Berg TJ, Greve EL. Functional characteristics of blue-on-yellow perimetric thresholds in glaucoma. Invest Ophthalmol Vis Sci. 1995 Jul;36(8):1665-74.</citation>
    <PMID>7601646</PMID>
  </results_reference>
  <results_reference>
    <citation>Sample PA, Taylor JD, Martinez GA, Lusky M, Weinreb RN. Short-wavelength color visual fields in glaucoma suspects at risk. Am J Ophthalmol. 1993 Feb 15;115(2):225-33.</citation>
    <PMID>8430733</PMID>
  </results_reference>
  <results_reference>
    <citation>Anderson AJ, Johnson CA. Frequency-doubling technology perimetry. Ophthalmol Clin North Am. 2003 Jun;16(2):213-25. Review.</citation>
    <PMID>12809159</PMID>
  </results_reference>
  <results_reference>
    <citation>Anderson AJ, Johnson CA, Fingeret M, Keltner JL, Spry PG, Wall M, Werner JS. Characteristics of the normative database for the Humphrey matrix perimeter. Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1540-8.</citation>
    <PMID>15790927</PMID>
  </results_reference>
  <results_reference>
    <citation>Artes PH, Hutchison DM, Nicolela MT, LeBlanc RP, Chauhan BC. Threshold and variability properties of matrix frequency-doubling technology and standard automated perimetry in glaucoma. Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2451-7.</citation>
    <PMID>15980235</PMID>
  </results_reference>
  <results_reference>
    <citation>Mafei L, Fiorentini A. Electroretinographic responses to alternating gratings before and after section of the optic nerve. Science. 1981 Feb 27;211(4485):953-5.</citation>
    <PMID>7466369</PMID>
  </results_reference>
  <results_reference>
    <citation>Bowd C, Tafreshi A, Zangwill LM, Medeiros FA, Sample PA, Weinreb RN. Pattern electroretinogram association with spectral domain-OCT structural measurements in glaucoma. Eye (Lond). 2011 Feb;25(2):224-32. doi: 10.1038/eye.2010.203. Epub 2010 Dec 24.</citation>
    <PMID>21183943</PMID>
  </results_reference>
  <results_reference>
    <citation>Bowd C, Tafreshi A, Vizzeri G, Zangwill LM, Sample PA, Weinreb RN. Repeatability of pattern electroretinogram measurements using a new paradigm optimized for glaucoma detection. J Glaucoma. 2009 Aug;18(6):437-42. doi: 10.1097/IJG.0b013e31818c6f44.</citation>
    <PMID>19680050</PMID>
  </results_reference>
  <results_reference>
    <citation>Bowd C, Vizzeri G, Tafreshi A, Zangwill LM, Sample PA, Weinreb RN. Diagnostic accuracy of pattern electroretinogram optimized for glaucoma detection. Ophthalmology. 2009 Mar;116(3):437-43. doi: 10.1016/j.ophtha.2008.10.026. Epub 2009 Jan 22.</citation>
    <PMID>19167080</PMID>
  </results_reference>
  <results_reference>
    <citation>Tafreshi A, Racette L, Weinreb RN, Sample PA, Zangwill LM, Medeiros FA, Bowd C. Pattern electroretinogram and psychophysical tests of visual function for discriminating between healthy and glaucoma eyes. Am J Ophthalmol. 2010 Mar;149(3):488-95. doi: 10.1016/j.ajo.2009.09.027.</citation>
    <PMID>20172073</PMID>
  </results_reference>
  <results_reference>
    <citation>Ventura LM, Porciatti V. Restoration of retinal ganglion cell function in early glaucoma after intraocular pressure reduction: a pilot study. Ophthalmology. 2005 Jan;112(1):20-7.</citation>
    <PMID>15629815</PMID>
  </results_reference>
  <results_reference>
    <citation>Bach M, Unsoeld AS, Philippin H, Staubach F, Maier P, Walter HS, Bomer TG, Funk J. Pattern ERG as an early glaucoma indicator in ocular hypertension: a long-term, prospective study. Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4881-7.</citation>
    <PMID>17065502</PMID>
  </results_reference>
  <results_reference>
    <citation>Ventura LM, Sorokac N, De Los Santos R, Feuer WJ, Porciatti V. The relationship between retinal ganglion cell function and retinal nerve fiber thickness in early glaucoma. Invest Ophthalmol Vis Sci. 2006 Sep;47(9):3904-11.</citation>
    <PMID>16936103</PMID>
  </results_reference>
  <results_reference>
    <citation>Banitt MR, Ventura LM, Feuer WJ, Savatovsky E, Luna G, Shif O, Bosse B, Porciatti V. Progressive loss of retinal ganglion cell function precedes structural loss by several years in glaucoma suspects. Invest Ophthalmol Vis Sci. 2013 Mar 28;54(3):2346-52. doi: 10.1167/iovs.12-11026.</citation>
    <PMID>23412088</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>electroretinogram pattern</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

